DAWN$10.5
Chart
Performance
Key Stats
AI DAWN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldDay One Biopharmaceuticals presents a mixed investment profile. While its focus on critical pediatric diseases aligns with strong thematic trends, its current financial performance indicates a need for caution. The stock's technicals show recent strength but also suggest potential short-term volatility.
Thematic
Day One Biopharmaceuticals is positioned within a high-impact thematic area focused on treating rare and aggressive childhood cancers. Advances in precision medicine and a growing understanding of genetic drivers of cancer are strong tailwinds for companies in this space.
Fundamental
Day One Biopharmaceuticals is a clinical-stage company with no current revenue from product sales. Its financial health relies on cash reserves and future financing. The company is not yet profitable and has significant operating expenses related to R&D and clinical trials.
Technical
The stock has shown recent upward momentum, trading above key moving averages, but is showing signs of potential overbought conditions on shorter timeframes. Investors should monitor for potential pullbacks or continued strength based on market sentiment and news.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 90 |
| Precision Medicine & Targeted Therapies | 92 |
| Unmet Medical Need | 88 |
| Clinical Trial Progress | 80 |
| Biotech Sector Trends | 75 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Debt Level | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 65 |
| Volume | 60 |
| Short-term Performance | 70 |
| Support/Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprises
The company has exceeded earnings per share (EPS) estimates in several recent quarters, including a significant positive surprise of 93.34% in Q3 2024 and 20.9% in Q2 2025.
Focused on High-Growth Area
Day One Biopharmaceuticals is focused on developing 'class medicines for childhood and adult diseases,' with lead product candidates in clinical trials for pediatric low-grade glioma and other cancers, a potentially high-impact and growing therapeutic area.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with a Net Income of -$95.496 million in 2024 and -$188.917 million in 2023, indicating it is not yet profitable.
Negative P/E Ratio and High PS Ratios
The Price-to-Earnings (PE) ratio is negative (-11.2 TTM, -13.4 in 2024) due to losses. Quarterly Price-to-Sales (PS) ratios are high in some periods (e.g., 26.1 in Q1 2025), suggesting a high valuation relative to current revenue, especially for an unprofitable company.
Calendar
August 2025
6
Next Earnings Date
H: $-0.25
A: $-0.34
L: $-0.40
H: 37.20M
A: 34.90M
L: 33.00M
Profile
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Seasonals
Price Target
26.25 USD
The 39 analysts offering 1 year price forecasts for DAWN have a max estimate of 36.00 and a min estimate of 18.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Directly related as the owner of the 'Dawn' dish soap brand, a leading global consumer goods company.
Weight: 95
Major global competitor to Procter & Gamble in household, personal care, and food products.
Weight: 92
Key competitor in household cleaning products, including dishwashing (Finish brand), and health and hygiene.
Weight: 90
Prominent global consumer products company with strong presence in oral care, personal care, and household care.